



Outstanding innovation & technology
transforming patient-specific surgery and
health literacy.

Investor Presentation
June 2021

Singular Health Group Limited | ASX: SHG | ABN 58 639 242 765



www.singular.health

Important notice and disclaimer



This presentation ("Presentation") has been prepared by Singular Health Group Ltd ("Singular Health" or "Company"). You must read and accept the conditions in this notice before considering the information set out in or referred to in this Presentation. If you do not agree, accept or understand the terms on which this Presentation is supplied, or if you are subject to the laws of any jurisdiction in which it would be unlawful to receive this Presentation or which requires compliance with obligations that have not been complied with in respect of it, you must immediately return or destroy this Presentation and any other confidential information supplied to you by Singular Health. By accepting this document, you acknowledge and agree to the conditions in this notice and agree that you irrevocably release Singular Health from any claims you may have (presently or in the future) in connection with the provision or content of this Presentation.

NO OFFER

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction (and will not be lodged with the ASIC). This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares of Singular Health and does not and will not form any part of any contract for the acquisition of shares of Singular Health.

SUMMARY INFORMATION

This Presentation contains summary information about Singular Health, its subsidiaries and their activities which is current as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Singular Health or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act. While Singular Health has taken every effort to ensure the accuracy of the material in the presentation, neither the Company nor its advisers have verified the accuracy or completeness of the information, or any statements and opinion contained in this Presentation.

NOT INVESTMENT ADVICE

Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Singular Health and the impact that different future outcomes may have on Singular Health. This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. Singular Health is not licensed to provide financial product advice in respect of Singular Health shares. Cooling off rights do not apply to the acquisition of Singular Health shares.

INVESTMENT RISK

An investment in Singular Health shares is subject to known and unknown risks, some of which are beyond the control of Singular Health. Singular Health does not guarantee any particular rate of return or the performance of Singular Health nor does it guarantee any particular tax treatment. An investment in Singular Health should be considered as Highly Speculative and High Risk due to the start up nature of the Company and its proposed business.

FINANCIAL DATA

All dollar values in this Presentation are in Australian dollars (A\$ or AUD) unless otherwise stated.

FORWARD-LOOKING STATEMENTS

This Presentation may contain forward looking statements. The words 'anticipate', 'believe', 'expect', 'project', 'forecast', 'estimate', 'likely', 'intend', 'should', 'could', 'may', 'target', 'plan' and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. You should not place undue reliance on forward- looking statements and neither Singular Health nor any of its directors, employees, advisers or agents assume any obligation to update such information.

DISCLAIMER

None of Singular Health's respective advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorized, permitted or caused the issue, submission, dispatch or provision of this Presentation and, except to the extent referred to in this Presentation, none of them makes or purports to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by any of them. To the maximum extent permitted by law, Singular Health and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in an investment in Singular Health and the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. To the maximum extent permitted by law, Singular Health and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation. Statements made in this Presentation are made only as the date of this Presentation. The information in this Presentation remains subject to change without notice. This presentation has been authorised for release by the Managing Director, Thomas Hanly.

Investor highlights



3D Printing: Singular Health is a 25% stakeholder in what will be one of the largest dedicated medical 3D printing facilities in Australia.



Enterprise: Integration of Virtual Surgical Planning (VSP) is underway with Lyka Smith to lead Australian distribution at \$300/month with 50 initial orders.



Disruptive: Completely platform neutral architecture for 3D imaging and surgery planning with the potential to disrupt and gain market share from existing solutions.



Scalable: Singular Health is implementing a “Direct to Patient”, “Direct to Practitioner” model with recurring revenues and potential virality.



Governance and Funding: Strong Board with ASX Medical and Technology expertise. Well funded with clean capital structure and low burn rate.



Research and Development: Continued access to non-dilutive funding with strong strong research and development pipeline leveraging publicly funded research organisations including universities and CSIRO.

\$4.48^{USD}BN

The Global Market¹ for Medical Software &
3D Printing

“

Accelerating the process of surgical planning and preparation through AI-driven segmentation and local additive manufacturing capabilities is key to creating significant value in this rapidly growing market of patient-specific surgery.

- Thomas Hanly, CEO


Company snapshot

Share on Issue	102,798,867
Share Price as at 14/06/2021	\$0.35
Market Cap	\$35,979,603
Cash at Bank	\$4.3M
% Escrowed	42.2%
Chairman	Howard Digby
CEO/MD	Thomas Hanly
Sector	Medical Technology

Founded in 2017, **Singular Health Group Ltd** is an Australian-based medical technology company with a proprietary volumetric rendering platform which leverages existing 2D radiological images to generate fully-immersive, patient-specific 3D/VR models.

Singular Health recently acquired 25% shareholding in a medical-grade 3D printing company in Melbourne and Virtual Surgical Planning software (VSP). These investments set in motion the **Scan to Surgery** initiative. A world first, vertically integrated Singular Health platform.

SHARE PRICE 22/03/2021 to 14/06/2021



LIQUIDITY

Free Float
57.6%



Escrowed
42.4%

Developing better health literacy & patient engagement

Patients with low health literacy were

59%


More likely to be readmitted after surgery²

and only...

40%

Australians have adequate health literacy³

Yet...



Demand is high

24%

&

12%

=

80 million
CT Scans⁴

&

Of **Americans** had a CT Scan in 2019⁴

Of **Americans** had an MRI⁴

40 million
MRI Scans⁴

Visualising better patient outcomes



Cross Platform



Affordable



Health Literacy
and Engagement



Improved
Treatment Plan
Adherence

How Singular Health is Developing Better Health Literacy

85% of patients want to see their scans – a recent American study finding 85% of patients wanted to see their radiological images⁵.

Using 3Dicom, practitioners can annotate, measure and even add video/voice recordings and share these files with patients to view in 3D on mobile, tablet, desktop, laptop, and even VR.



Patient Specific Implants provide:



Improved alignment⁶



Reduced intra-operative blood loss⁶



Reduced length of hospital stay⁶



Significant cost benefits⁶

Delivering benefits from the initial diagnostic stage right through to surgery.



Scan



PACS



3D/VR Scan Review



Artificial Intelligence



Virtual Surgical Planning



3D Printing



Surgery

Existing Infrastructure

Singular Health Platform

Scan – leveraging existing infrastructure

Singular Health utilizes existing CT, MRI, & PET scanners which typically capture a series of images as multiple 2D 'slices' of the body.

Singular Health's platform reads and accurately interprets the DICOM meta-tags on each and every slice during the scan load.

\$16 **USD Billion**

Global medical imaging market⁸

27M


Diagnostic Images in Australia 2017⁷


1000

CT Scanners in Australia⁷

359

MRI scanners in Australia 2017⁷





Estimated market value⁹

\$2.66 USD Billion
and CAGR **5%**

Global Picture Archiving & Communications Systems (PACS)

PACS is the infrastructure which medical images are stored and transferred between the scanner and the server.

Singular Health's medical software product **3Dicom**, integrates with the vast majority of PACS servers, allowing for the easy retrieval of DICOM files for viewing in fully-immersive 3D/VR.



3D/VR scan review

Global Medical Imaging estimated
market value¹⁰

\$2.4 USD
Billion

and
CAGR **8.18%**

Interactive 3D models on
desktop and has been
technically proven to work on
standalone VR headsets,
tablets and mobile phones.



3Dicom aims to **diagnose, analyse, and provide patient education/informed consent** using the raw radiological images across a diverse range of medical specialties.

Existing Infrastructure



Scan



PACS



3D/VR Scan
Review



Artificial
Intelligence



Virtual
Surgical
Planning



3D Printing



Surgery

Singular Health Platform

Global Artificial Intelligence in Medicine estimated market value

\$1.5 USD Billion
and CAGR **30.4%**



Accelerated Semi-automated segmentation



Reduced manual process

Application of AI into Scan to Surgery

AI will enable pre-operative planning and intra-operative guidance thereby **saving time**, **reducing medical error** and **improving overall patient management** and outcome.

Accurate Diagnosis



Improved Analysis



Better Decision-making




Segmented spine

10 minutes
SHG AI model

v

Up to 4-5 hours
Manual processing



Global Surgical Planning Software
market estimated value ¹¹

\$84 USD
Million

and
CAGR **5.2%**

Global Surgical Simulation &
Training market estimated value ¹²


\$337 USD
Million

and
CAGR **16.4%**

How it works

Radiological scans are converted from 2D images into editable 3D computer aided design (CAD) files.

These are then used to design drill and cutting guides, splints and implants.



2D

converted to

3D

Existing Infrastructure



Scan



PACS



3D/VR Scan
Review



Artificial
Intelligence



Virtual
Surgical
Planning



3D Printing



Surgery

Singular Health Platform

Singular Health has invested \$300,000 to build one of Australia's largest dedicated medical 3D printing facility which will accelerate typical surgical planning and reduce lead times for surgeries in Australia through local printing.



Global Medical 3D printing market estimated value¹³

\$2.4 USD BILLION

and CAGR

16.3%

Existing Infrastructure



Scan



PACS



3D/VR Scan Review



Artificial Intelligence



Virtual Surgical Planning



3D Printing



Surgery



Will enable surgeons to view an interactive step-by-step surgical plan with all of their notes from their pre-surgical planning session.




Medico-legal; records steps taken. Checklists will create a digital record of surgeries for the surgical staff, and 'medical precedents'.



Use as communications/training tool for briefing all members of surgical team prior to complex surgeries.



Preoperative & intra-operative surgical plans will be available via 3Dicom Surgical & 3DicomVSP for review on tablet in theatre and in Virtual Reality prior to surgery.



Existing Infrastructure



Scan



PACS



3D/VR Scan Review



Artificial Intelligence



Virtual Surgical Planning



3D Printing



Surgery

Singular Health Platform

Regulatory pathway



Singular Health has commenced the development of a Quality Management System (QMS) to proceed with **ISO13485** Certification.



Singular Health will continue to pursue AI applications through its strong research and innovation program with leading institutions.



AI models require clearance, through the **FDA510(k)** process using predicate devices for most models with an anticipated processing evaluation period of 6-7 months from application.



MedVR currently registered on **Australian Register of Therapeutic Goods** (ARTG) as Class I Medical Device



Singular Health anticipates application for **TGA Class II** registration by Q4 CY2021 and **FDA510(k)** clearance for 3Dicom Surgical & 3DicomVSP in Q1 CY2022

The pathway to
enterprise sales



Board and senior management



Howard Digby

Non-Executive Chairman

Over 25 years' experience managing technology-related businesses in the Asia Pacific region. Howard is Currently a Non-Executive Director of 4DS Memory, Elsieht, Cirralto, Vortiv and previously ImeHXS.



Thomas Hanly

*Managing Director &
Chief Executive Officer*

A seasoned executive having held various board positions with a number of privately held companies in Australia and Singapore.. Holding a Bachelor degree in Resource and Environmental Economics.



Andrew Just

Non-Executive Director

Over 25 years of global senior executive experience in the healthcare industry. With a Bachelors degree in economics & business law from Macquarie University, a diploma in health economics from Monash University, and an MBA from AGSM University of Sydney.



Denning Chong

Non-Executive Director

One of the founders of Singular Health, Denning has been the principal of James Chong lawyers since 2004. Denning has held various directorship positions working with companies across the medical technology, property and financial sectors.



Prof. Kwang Guan Tay

*Executive Director of
Research & Innovation*

Holding a PhD from the Centre for Molecular Immunology and Instrumentation from UWA, an MBA and Bachelor of Science (Biotechnology and Biological Sciences Double Major) with Honours (BSc(Hons)) from Murdoch University.



James Hill

Chief Operating Officer

An experienced professional in the commercial technology sector, having held directorships with a number of private companies. James graduated from UWA with a Bachelor of Commerce (Marketing and Management).



Thomas Morrell

Chief Technology Officer

Graduating from Staffordshire University with First Class Honours in CGI & Digital Effects, Thomas has worked for a number of well-known companies developing photogrammetry, 360 media and mixed reality applications.



Contact Us

SALES / PARTNERSHIPS

Email:
sales@singular.health

Phone:
1300 167 795

INVESTOR RELATIONS

Email:
jhill@singular.health

Phone:
+61 413 825 646

ASX: SHG | www.singular.health



1. Frost & Sullivan, accessed June 2021, <https://ww2.frost.com/>
2. Baker, S., Malone, E., Graham, L., Dasinger, E., Wahl, T., Titan, A., Richman, J., Copeland, L., Burns, E., Whittle, J., Hawn, M., & Morris, M. (2020). Patient-reported health literacy scores are associated with readmissions following surgery. *Am J Surg*, 220(5), 1138-1144. <https://doi.org/10.1016/j.amjsurg.2020.06.071>
3. Australian Bureau of Statistics, accessed June 2021, <https://www.abs.gov.au/>
4. Papanicolas, I., Woskie, L. R., & Jha, A. K. (2018). Health Care Spending in the United States and Other High-Income Countries. *JAMA*, 319(10), 1024-1039. <https://doi.org/10.1001/jama.2018.1150>
5. Schwarzkopf, R., Brodsky, M., Garcia, G. A., & Gomoll, A. H. (2015). Surgical and Functional Outcomes in Patients Undergoing Total Knee Replacement With Patient-Specific Implants Compared With “Off-the-Shelf” Implants. *Orthopaedic Journal of Sports Medicine*, 3(7), 2325967115590379. <https://doi.org/10.1177/2325967115590379>
6. Cabarrus, M., Naegar, D., Rybkin, A. & Qayyum, A. (2015). Patients prefer results from the ordering provider and access to their radiology reports. *Journal of the American College of Radiology*, 12(6), 556-562. <https://doi.org/10.1016/j.jacr.2014.12.009>
7. The Royal Australian and New Zealand College of Radiologists (2019), *Radiology At a Glance Australia*. <https://www.ranzcr.com/college/document-library/radiology-at-a-glance-Australia>
8. Grand View Research, (2020). *Medical Imaging Market Size, Share & Trends Analysis Report By Product (X-ray, Computed Tomography, Ultrasound, MRI, Nuclear Imaging), By End Use, By Region, And Segment Forecasts, 2021 – 2028*. <https://www.grandviewresearch.com/industry-analysis/medical-imaging-systems-market>.

8. BioSpace, (2020). *PACS and RIS Market: PACS Segment to Capture Largest Market Share*. <https://www.biospace.com/article/pacs-and-ris-market-pacs-segment-to-capture-largest-market-share>
9. Grand View Research, (2020). *Medical Image Analysis Software Market Size, Share & Trends Analysis Report By Software Type, By Modality (Radiographic, Ultrasound), By Imaging Type, By End Use, By Application, And Segment Forecasts, 2020 – 2027*. <https://www.grandviewresearch.com/industry-analysis/medical-image-analysis-software-market>
10. Allied Market Research, (2019). *Global Preoperative Surgical Planning Software Market to Reach \$126.81 Million, Globally, by 2026 at 5.2% CAGR: AMR*. Cision PR Newswire, 5 June, accessed June 2021, <https://www.prnewswire.com/news-releases/global-preoperative-surgical-planning-software-market-to-reach-126-81-million-globally-by-2026-at-5-2-cagr-amr-300862389.html>
11. Prescient & Strategic Intelligence, (2020). *Surgical Simulation Market Research Report: By Offering (Products {Endoscopic, Laparoscopic, Cardiac, Gynecological, Arthroscopic, Neurological}, Services {Educational, Technical}), End User (Academic and Research Institutes, Hospitals, Surgical Clinics, Military Organizations) - Global Industry Analysis and Growth Forecast to 2030*. <https://www.psmarketresearch.com/market-analysis/surgical-simulation-market>
12. Markets and Markets, (2021). *3D Printing Medical Devices Market by Component (3D Printer, 3D Bioprinter, Material, Software, Service), Technology (EBM, DMLS, SLS, SLA, DLP, Polyjet), Application (Surgical Guides, Prosthetics, Implants), User (Hospital, ASCs) - Global Forecast to 2026*. <https://www.marketsandmarkets.com/market-reports/3d-printing-medical-devices-market-90799911.html>